Intraoperative Kit for AuNP-Tissue Grafts

项目摘要/摘要--摘自第一阶段STTR奖 这项拟议的技术是一种术中试剂盒，它由一种液体溶液组成，它将结合黄金 纳米颗粒(AuNPs)在几分钟内即可植入组织移植物。组织移植，如用于前交叉韧带重建的组织移植 手术后，移植物很少能实现100%的同化，从而导致一系列问题。一个潜在的解决方案是 对移植物进行改进，以增强整合，减少炎症，从而改善临床 结果。这项技术的创新是开发了术中附着AuNPs的工具包 在手术室环境中的移植物。这些移植物可以是自体移植物或商业上可获得的同种移植物，异种移植物， 或任何其他天然材料，如胶原蛋白或3D打印组织。该项目的具体目标将 验证术中AuNP-组织结合方法的概念。两个具体目标将严格 追求，包括1)通过生产AuNP移植物来优化术中套件方法，以减少 炎症，同时通过体外研究增加细胞增殖，以及2)验证炎症 在体内重建前交叉韧带模型中改良移植物的调节能力和细胞增殖。 目前，还没有商业技术来修改生物移植物以促进重塑和 减少炎症。这项研究的意义在于发展了一种术中改良的方法 生物移植物，以提高临床表现。PI和分包PI具有专业知识来追求 STTR第一阶段计划的目标；他们拥有多年开发纳米材料组织的经验 生物复合材料公司，并参与了几家初创公司的业务。

Project Summary/Abstract - from the Phase I STTR award The proposed technology is an intraoperative kit comprised of a liquid solution which will conjugate gold nanoparticles (AuNPs) to tissue grafts within minutes. Tissue grafts, such as those used in ACL reconstruction surgery, rarely achieve 100% graft assimilation, thereby leading to a host of problems. A potential solution is to modify the grafts in order to enhance integration and reduce inflammation and thus improve clinical outcomes. The innovation of this technology is the development of the intraoperative kit to attach AuNPs to grafts in surgical suite settings. These grafts can be autografts or commercially available allografts, xenografts, or any other natural materials such as collagen or 3D printed tissues. The specific aims of the project will validate the concept of an intraoperative AuNP-tissue conjugation method. Two specific aims will be rigorously pursued, which include 1) optimizing the intraoperative kit method by producing AuNP grafts that reduce inflammation while increasing cellular proliferation via in vitro studies and 2) validating the inflammation modulation ability and cellular proliferation of the modified grafts in an ACL reconstruction in vivo model. Currently, there are no commercial technologies that modify biologic grafts in order to promote remodeling and reduce inflammation. The significance of this research is the development of an intraoperative method to modify biological grafts to improve clinical performance. The PI and sub-contract PI have the expertise to pursue the aims of this STTR Phase 1 proposal; they have years of experience developing nanomaterial-tissue bionanocomposites and have been involved with several start-up companies.